Prostate cancer screening could be improved through accounting for genetic factors that cause noncancer-related variations in PSA levels, according to study results presented at American Association for Cancer Research Annual Meeting.
Genetic adjustment of PSA could reduce unnecessary testing and overdiagnosis of low-risk prostate cancer and increase detection of aggressive tumors, researchers wrote.
“PSA is one of the most widely used prostate cancer biomarkers and is used for detection and also in disease management,” Linda Kachuri, MPH, PhD, postdoctoral scholar in the department